Adverum Biotechnologies has a new chief legal officer in its sights
Adverum Biotechnologies Inc., a clinical-stage gene therapy company targeting ocular and rare diseases Peter Soparkar as its chief legal officer.
Soparkar has over 15 years of legal experience, including corporate development, corporate governance, legal, regulatory, commercial, and public compliance activities, for biotechnology companies as well as at the law firm Latham & Watkins. Prior to joining Adverum, Soparkar was chief legal officer and head of human resources at Counsyl Inc., a genetic diagnostics company, where he also served as corporate secretary and head of compliance. He helped negotiate and execute the sale of Counsyl to Myriad Genetics in 2018. From 2006 – 2016, Soparkar was at Jazz Pharmaceuticals. Prior to Jazz, Soparkar worked at Latham & Watkins in London and San Francisco. He received a J.D. from New York University and a B.A. in economics and politics from Oberlin College.
“We are pleased to welcome Peter to our leadership team as he brings deep legal and organizational experience,” said Leone Patterson, Adverum’s CEO. “His breadth of industry knowledge and expertise managing through strategic business initiatives will be invaluable as we continue to advance our clinical and strategic plans to advance and expand our pipelines.”